Anebulo Pharmaceuticals
ANEB
ANEB was delisted on the 27th of February, 2026.
10 hedge funds and large institutions have $29.5M invested in Anebulo Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 1 closing their positions.
14% more capital invested
Capital invested by funds: $25.8M → $29.5M (+$3.72M)
0% more funds holding
Funds holding: 10 → 10 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
0.01% less ownership
Funds ownership: 17.96% → 17.95% (-0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$60.9K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$10.8K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.18K |
| 4 |
Morgan Stanley
New York
|
+$7 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$53.7K |
| 2 |
LCM
Laurion Capital Management
New York
|
-$37.1K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$3K |
| 4 |
BlackRock
New York
|
-$2.46K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
2L
1
22NW LP
Seattle,
Washington
| $23.8M | – | – | – |
|
|
MP
2
Mangrove Partners
Greenwich,
Connecticut
| $2.83M | -$53.7K | -7,840 | -2% |
|
|
LCM
3
Laurion Capital Management
New York
| $1.48M | -$37.1K | -5,417 | -2% |
|
|
IC
4
Ikarian Capital
Dallas,
Texas
| $1.23M | +$60.9K | +8,890 | +5% |
|
|
BFM
5
Boothbay Fund Management
New York
| $123K | – | – | – |
|
|
6
BlackRock
New York
| $53K | -$2.46K | -360 | -5% |
|
|
7
UBS Group
Zurich,
Switzerland
| $15K | +$10.8K | +1,576 | +272% |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $5K | +$5.18K | +756 | New |
|
|
9
Osaic Holdings
Scottsdale,
Arizona
| – | -$3K | -500 | Closed |
|
|
10
Morgan Stanley
New York
| – | +$7 | +1 | +50% |
|
ANEB Hedge Fund Activity: Q1 2022 in Review
10 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Anebulo Pharmaceuticals (ANEB) for Q1 2022, worth a combined $29.5M — up 14% from $25.8M a quarter earlier.
Fund positioning in ANEB was balanced in Q1 2022: 1 fund opened new positions, 1 closed out, 3 added to existing stakes and 3 trimmed.
The largest buyer was Ikarian Capital, adding an estimated $60.9K. The largest seller was Mangrove Partners, cutting an estimated $53.7K.
- 10 institutional investors held Anebulo Pharmaceuticals (ANEB) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $29.5M of Anebulo Pharmaceuticals stock for Q1 2022, up 14% quarter-over-quarter.
- 1 fund opened new Anebulo Pharmaceuticals positions in Q1 2022 and 1 closed out, a net change of 0 holders.
- The largest Anebulo Pharmaceuticals buyer in Q1 2022 was Ikarian Capital, an estimated $60.9K added.
- The largest Anebulo Pharmaceuticals seller in Q1 2022 was Mangrove Partners, an estimated $53.7K sold.
Based on aggregated 13F filings for Q1 2022.